vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and MERCURY SYSTEMS INC (MRCY). Click either name above to swap in a different company.

Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $235.8M, roughly 1.1× MERCURY SYSTEMS INC). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 11.5%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs -2.6%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Mercury Systems, Inc. is a technology company serving the aerospace and defense industry. It designs, develops and manufactures open architecture computer hardware and software products, including secure embedded processing modules and subsystems, avionics mission computers and displays, rugged secure computer servers, and trusted microelectronics components, modules and subsystems.

ASND vs MRCY — Head-to-Head

Bigger by revenue
ASND
ASND
1.1× larger
ASND
$267.3M
$235.8M
MRCY
Growing faster (revenue YoY)
ASND
ASND
+30.8% gap
ASND
42.3%
11.5%
MRCY
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
-2.6%
MRCY

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ASND
ASND
MRCY
MRCY
Revenue
$267.3M
$235.8M
Net Profit
$-2.9M
Gross Margin
90.5%
99.6%
Operating Margin
72.9%
Net Margin
-1.2%
Revenue YoY
42.3%
11.5%
Net Profit YoY
EPS (diluted)
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
MRCY
MRCY
Q1 26
$235.8M
Q4 25
$267.3M
$232.9M
Q3 25
$230.7M
$225.2M
Q2 25
$170.7M
$273.1M
Q1 25
$109.0M
$211.4M
Q4 24
$187.8M
$223.1M
Q3 24
$62.5M
$204.4M
Q2 24
$38.9M
$248.6M
Net Profit
ASND
ASND
MRCY
MRCY
Q1 26
$-2.9M
Q4 25
$-15.1M
Q3 25
$-65.9M
$-12.5M
Q2 25
$-42.0M
$16.4M
Q1 25
$-102.2M
$-19.2M
Q4 24
$-17.6M
Q3 24
$-107.1M
$-17.5M
Q2 24
$-118.1M
$-10.8M
Gross Margin
ASND
ASND
MRCY
MRCY
Q1 26
99.6%
Q4 25
90.5%
26.0%
Q3 25
89.5%
27.9%
Q2 25
80.1%
31.0%
Q1 25
82.6%
27.0%
Q4 24
91.9%
27.3%
Q3 24
80.6%
25.3%
Q2 24
68.2%
29.5%
Operating Margin
ASND
ASND
MRCY
MRCY
Q1 26
72.9%
Q4 25
-4.6%
Q3 25
5.1%
-3.8%
Q2 25
-33.5%
8.6%
Q1 25
-103.2%
-8.2%
Q4 24
-5.6%
Q3 24
-167.3%
-6.6%
Q2 24
-370.2%
-3.2%
Net Margin
ASND
ASND
MRCY
MRCY
Q1 26
-1.2%
Q4 25
-6.5%
Q3 25
-28.5%
-5.6%
Q2 25
-24.6%
6.0%
Q1 25
-93.7%
-9.1%
Q4 24
-7.9%
Q3 24
-171.5%
-8.6%
Q2 24
-303.9%
-4.3%
EPS (diluted)
ASND
ASND
MRCY
MRCY
Q1 26
$-0.04
Q4 25
$-0.26
Q3 25
$-0.21
Q2 25
$0.28
Q1 25
$-0.33
Q4 24
$-0.30
Q3 24
$-0.30
Q2 24
$-0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
MRCY
MRCY
Cash + ST InvestmentsLiquidity on hand
$665.3M
$331.8M
Total DebtLower is stronger
$591.5M
Stockholders' EquityBook value
$-175.8M
$1.5B
Total Assets
$1.4B
$2.5B
Debt / EquityLower = less leverage
0.40×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
MRCY
MRCY
Q1 26
$331.8M
Q4 25
$665.3M
$335.0M
Q3 25
$582.2M
$304.7M
Q2 25
$533.6M
$309.1M
Q1 25
$559.4M
$269.8M
Q4 24
$604.3M
$242.6M
Q3 24
$675.6M
$158.1M
Q2 24
$279.4M
$180.5M
Total Debt
ASND
ASND
MRCY
MRCY
Q1 26
$591.5M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
ASND
ASND
MRCY
MRCY
Q1 26
$1.5B
Q4 25
$-175.8M
$1.5B
Q3 25
$-188.0M
$1.5B
Q2 25
$-202.6M
$1.5B
Q1 25
$-205.0M
$1.5B
Q4 24
$-114.2M
$1.5B
Q3 24
$-105.1M
$1.5B
Q2 24
$-346.8M
$1.5B
Total Assets
ASND
ASND
MRCY
MRCY
Q1 26
$2.5B
Q4 25
$1.4B
$2.5B
Q3 25
$1.2B
$2.5B
Q2 25
$1.2B
$2.4B
Q1 25
$1.1B
$2.4B
Q4 24
$1.3B
$2.4B
Q3 24
$1.2B
$2.4B
Q2 24
$819.0M
$2.4B
Debt / Equity
ASND
ASND
MRCY
MRCY
Q1 26
0.40×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
MRCY
MRCY
Operating Cash FlowLast quarter
$58.2M
$6.4M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-0.8%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$73.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
MRCY
MRCY
Q1 26
$6.4M
Q4 25
$58.2M
$51.6M
Q3 25
$2.2M
Q2 25
$38.1M
Q1 25
$-15.5M
$30.0M
Q4 24
$-330.7M
$85.5M
Q3 24
$-14.7M
Q2 24
$71.8M
Free Cash Flow
ASND
ASND
MRCY
MRCY
Q1 26
$-1.8M
Q4 25
$45.7M
Q3 25
$-4.4M
Q2 25
$34.0M
Q1 25
$24.1M
Q4 24
$81.9M
Q3 24
$-20.9M
Q2 24
$61.4M
FCF Margin
ASND
ASND
MRCY
MRCY
Q1 26
-0.8%
Q4 25
19.6%
Q3 25
-1.9%
Q2 25
12.4%
Q1 25
11.4%
Q4 24
36.7%
Q3 24
-10.2%
Q2 24
24.7%
Capex Intensity
ASND
ASND
MRCY
MRCY
Q1 26
Q4 25
2.5%
Q3 25
2.9%
Q2 25
1.5%
Q1 25
2.8%
Q4 24
1.6%
Q3 24
3.1%
Q2 24
4.2%
Cash Conversion
ASND
ASND
MRCY
MRCY
Q1 26
Q4 25
Q3 25
Q2 25
2.33×
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons